Protocol I6F-MC-JJCA(b:) A Phase 1 Study of LY3039478 in Patients with Advanced or Metastatic Cancer
A study for patients with solid tumors or lymphoma using study drug LY3039478
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ7203
U.S. Govt. ID: NCT01695005
Contact: Nicole Lamanna: 646-317-5205 / nl2129@cumc.columbia.edu
Additional Study Information: This study is being done to see how safe an investigational drug (LY3039478) is and how well it will work to help people with advanced or metastatic cancer including solid tumors or lymphoma (cancerous growth of lymphoid tissue) including chronic lymphocytic leukemia (CLL blood cell cancer). The primary purpose of your participation in this study is to help answer the following research questions: How much LY3039478 should be given to patients with different types of cancer? To check for the safety of LY3039478 identified dose and any side effects that might be associated with it. What effects does LY3039478 have on the body? How effective LY3039478 is in treatment of cancer?
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Have you been diagnosed with advanced lymphoma or a solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Nicole Lamanna
nl2129@cumc.columbia.edu
646-317-5205